Bayer's Pipeline Wins Meet a Courtroom Deadline: Why the Market Isn't Cheering Yet
Published on 09/10/2026 at 17:21 | Editorial boerse-global.de
Bayer shareholders received a double dose of good news on Thursday, yet the stock barely budged. The FDA granted accelerated approval to the company's lung cancer drug Sevabertinib — marketed as Hyrnuo — as a first-line treatment, while management used an investor event to reaffirm its five-year targets for the Crop Science division and flesh out how it intends to get there. By midday, the shares were trading around EUR 48.90, marginally lower.
That muted reaction is not a verdict on the science or the agricultural strategy. It is a verdict on a single date on the calendar: September 14, when a US court hearing could signal whether Bayer is any closer to resolving the glyphosate litigation that has weighed on its valuation for years.
A Broader Label, a Bigger Addressable Market
The FDA's decision extends Sevabertinib's use to adults with locally advanced or metastatic, non-squamous, HER2-mutant non-small cell lung cancer who have not yet received prior treatment. The drug had already cleared the agency in November 2025 for previously treated patients. Adding treatment-naive patients matters commercially because they represent the largest group of eligible cases.
The approval rests on data from the Phase I/II SOHO-01 trial (NCT05099172). Among 69 treatment-naive participants, Sevabertinib produced an objective response rate of 75 percent — 6 percent complete responses and 70 percent partial responses. Responses lasted at least six months in 73 percent of responders and at least twelve months in 38 percent. Patients take 20 milligrams orally twice daily with food.
Continued approval is contingent on the confirmatory Phase III SOHO-02 study (NCT06452277), a standard condition for accelerated authorizations. The most common side effects, affecting more than 20 percent of patients, included diarrhea, rash, mouth inflammation, nail bed infection, nausea and weight loss.
Should investors sell immediately? Or is it worth buying Bayer?
HER2 mutations appear in roughly 2 to 4 percent of all NSCLC cases — a narrow but well-defined niche. Sevabertinib, a reversible tyrosine kinase inhibitor, emerged from Bayer's alliance with the Broad Institute, MIT and Harvard, and has already secured approval in China from the NMPA and in Japan from the MHLW.
Competition is not standing still. Boehringer Ingelheim's Hernexeos posted a 77 percent objective response rate in first-line use, close to Sevabertinib's figure, though the two drugs were tested in different populations and trial designs. The contest for HER2-mutant lung cancer patients looks set to stay fierce.
Two Analysts, Two Targets, One Unresolved Question
Deutsche Bank Research kept its "Buy" rating and EUR 60 price target, with analyst Virginie Boucher-Ferte now seeing the agrochemical cycle as the only meaningful risk left — other drags on the stock have largely dissipated. Barclays' James Gordon went further on Monday, lifting his target from EUR 60 to EUR 70 with an "Overweight" rating. Crucially, Barclays ties that upgrade explicitly to the September 14 court date and the possibility it yields clues about a settlement.
That is the crux. Until the legal uncertainty around glyphosate is reduced, a structural valuation discount stays baked into the share price — no matter how well Crop Science performs or how many FDA nods the pharma unit collects.
The technical picture offers little resistance either way. At around EUR 48.90, the stock sits close to its 50-day average of EUR 48.67 and roughly 9 percent below its 52-week high of EUR 53.86 set in early July. An RSI of 52.4 suggests no overheating, leaving room for the recovery to continue — a run that has already added about 90 percent since the 52-week low of EUR 25.78 last November. Wednesday's close was EUR 49.06, down 0.6 percent on the day, and over twelve months the shares are up 75 percent, a sign that investors have been rewarding Bayer's fundamental repositioning while treating individual regulatory milestones as confirmation rather than surprise.
What Could Go Right — and What Could Go Wrong
Should the September 14 hearing point toward a negotiated resolution or more favorable jurisprudence, the path to a re-rating opens up — precisely what Barclays assumes with its jump to EUR 70. Sevabertinib's 75 percent response rate gives the oncology pipeline a tangible argument, even with full approval still hinging on SOHO-02. And at Crop Science, management's reaffirmed five-year targets and sharper roadmap read to Boucher-Ferte as evidence that operational risks are receding.
The bear case mirrors it. If the hearing produces no clear signal or goes against Bayer, the glyphosate complex will keep dragging on the stock despite good news elsewhere. Sevabertinib's approval is accelerated and therefore conditional; a setback in SOHO-02 would be a warning sign of the kind Novartis just experienced, when its failed Phase III Del-desiran program prompted analysts to slash ratings. Macro headwinds add pressure: the ECB raised its key rate on Thursday for the second time this year to 2.50 percent, while oil has climbed above USD 100 a barrel. A tougher rate environment makes Bayer's still-heavy debt burden more expensive and tends to compress the valuation headroom that upgrades like Barclays' depend on.
The Date That Matters Most
As long as glyphosate remains unresolved, the stock looks range-bound between its 50-day average of EUR 48.67 and the 52-week high of EUR 53.86, with pharma or agricultural headlines alone unlikely to force a sustained breakout. If the legal picture turns Bayer's way on September 14, the EUR 60 to EUR 70 targets could quickly come back into focus. If clear progress fails to materialize, the litigation will keep capping the valuation — even if third-quarter results on November 3 land solidly. For investors, next week's court hearing is the real key event, ahead of the next earnings report.
Ad
Bayer Stock: New Analysis - 10 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
